News for MEI Pharma, Inc. (MEIP)

MEI Pharma, Inc. (Nasdaq: MEIP) (the ”œCompany”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the

We are pleased with the progress our accounts and funds achieved in 2024. Click here to read more.

MEI Pharma (MEIP) shares jumped 9% on news the company sold the rights to ME-344 to Aardvark Therapeutics for $500K upfront and up to $62M in milestone payments. Read more here.

MEI Pharma stock hits 52-week low at $2.72 amid market challenges

MEI Pharma reviews strategic options amid fiscal changes

Laidlaw downgraded MEI Pharma (MEIP) to hold over concerns the company may cease operations. Read more here.

MEI Pharma stock downgraded amid strategic review and shutdown risk

Loading... Loading... Shares of CrowdStrike Holdings, Inc. CRWD fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock fr...

MEI Pharma (MEIP) said on Monday that the biotechnology company is planning to reduce workforce as part of strategic alternatives.

MEI Pharma (MEIP) stock falls as the company decides not to proceed with a second return of capital, as agreed in a corporation agreement in October. Read more here.

MEI Pharma halts capital return to focus on drug development

– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of...

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital,...

MEI Pharma, Inc. , a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David...

In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds.

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside.

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Infinity To Contact Him Directly To Discuss Their Op...

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...